Maggio Emilia, Mete Maurizio, Maraone Giorgia, Attanasio Marcella, Guerriero Massimo, Pertile Grazia
IRCCS Sacro Cuore Don Calabria Hospital, Via Don Sempreboni 5-Negrar 37024, Verona, Italy.
Department Computer Science, University of Verona, Strada le Grazie 15-37134, Verona, Italy.
J Ophthalmol. 2020 Feb 13;2020:7817542. doi: 10.1155/2020/7817542. eCollection 2020.
To report the long-term visual and anatomic outcomes of intravitreal injections for macular edema (ME) secondary to retinal vein occlusion (RVO) in a real-life clinical setting.
Retrospective interventional case series.
A total of 223 consecutive eyes with ME secondary to RVO, treated with the first three intravitreal Ranibizumab or dexamethasone injections between August 2008 and September 2018, were enrolled in the study. Subsequent retreatment was guided by best-corrected visual acuity (BCVA) and central macular thickness (CMT) measurements, aimed at achieving macular fluid regression and BCVA stability. BCVA and CMT were recorded at baseline and at subsequent annual time points. The mean number of injections administered each year and the incidence of adverse events were recorded.
The mean BCVA and CMT at baseline were 0.79 logMar (SD 0.71) and 615.7 m (SD 257.5), respectively. The mean follow-up (FU) period was 47.8 months (min 12-max 120). At 12 months, the mean BCVA and CMT had significantly improved to 0.62 logMar (SD 0.68; < 0.0001) and 401.04 m (SD 257.5), respectively. The mean follow-up (FU) period was 47.8 months (min 12-max 120). At 12 months, the mean BCVA and CMT had significantly improved to 0.62 logMar (SD 0.68; < 0.0001) and 401.04 .
Intravitreal Ranibizumab and/or dexamethasone injections were found to be effective at inducing a long-lasting improvement of BCVA and CMT in a real-life clinical setting. A safety profile similar to that already well-established in Ranibizumab and dexamethasone treatment was observed, as well as a steady decrease in the number of intraocular injections required. The results support intravitreal treatments for BRVO and CRVO in patient populations with similar characteristics in similar settings.
报告在实际临床环境中，玻璃体内注射治疗视网膜静脉阻塞（RVO）继发黄斑水肿（ME）的长期视觉和解剖学结果。
回顾性干预病例系列。
本研究纳入了2008年8月至2018年9月期间连续接受前三次玻璃体内注射雷珠单抗或地塞米松治疗的223例RVO继发ME患者的患眼。后续再治疗以最佳矫正视力（BCVA）和中心黄斑厚度（CMT）测量结果为指导，旨在实现黄斑区积液消退和BCVA稳定。在基线和随后的年度时间点记录BCVA和CMT。记录每年平均注射次数和不良事件发生率。
基线时平均BCVA和CMT分别为0.79 logMar（标准差0.71）和615.7μm（标准差257.5）。平均随访期为47.8个月（最短12个月 - 最长120个月）。在12个月时，平均BCVA和CMT分别显著改善至0.62 logMar（标准差0.68；P < 0.0001）和401.04μm。平均随访期为47.8个月（最短12个月 - 最长120个月）。在12个月时，平均BCVA和CMT分别显著改善至0.62 logMar（标准差0.68；P < 0.0001）和401.04。
在实际临床环境中，发现玻璃体内注射雷珠单抗和/或地塞米松可有效诱导BCVA和CMT的长期改善。观察到的安全性与雷珠单抗和地塞米松治疗中已确立的安全性相似，并且所需眼内注射次数稳步减少。这些结果支持在类似环境中对具有相似特征的患者群体进行玻璃体内治疗BRVO和CRVO。
